06996.HK
Antengene Corporation Limited
HKSE · Healthcare · Biotechnology · CN
HKD 3.31
+1.85%Year over year
Reported trailing growth
- Revenue
- +561.7%
- EBITDA
- +164.9%
- EBIT
- +154.8%
- EPS
- +122.2%
- Free cash flow
- +38.9%
- Operating cash flow
- +46.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -13.0%
- EBITDA
- +36.6%
- EBIT
- +34.5%
- Net income
- +25.1%
- EPS
- +25.5%
- Free cash flow
- +53.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026